Progenics Pharma (PGNX) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Needham & Company Reiterates Buy on Progenics Pharma (PGNX); Anticipates Oral Relistor Approval
March 14, 2016 8:01 AM EDTNeedham & Company reiterated a Buy rating and $11.00 price target on Progenics Pharmaceuticals (NASDAQ: PGNX). Needham is anticipating approval of oral Relistor on its April 19th PDUFA date, which will trigger a $50 million milestone payment from Valeant and should lead to a significant increase in Relistor... More
